Second Sight Medical Valuation

EYESDelisted Stock  USD 4.14  0.20  4.61%   
At this time, the company appears to be overvalued. Second Sight Medical has a current Real Value of $3.93 per share. The regular price of the company is $4.14. Our model measures the value of Second Sight Medical from inspecting the company fundamentals such as Shares Outstanding of 39.41 M, shares owned by institutions of 7.01 %, and Return On Equity of -19.02 as well as reviewing its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and selling overvalued stocks since, at some point, asset prices and their ongoing real values will draw towards each other.
Overvalued
Today
4.14
Please note that Second Sight's price fluctuation is very steady at this time. Calculation of the real value of Second Sight Medical is based on 3 months time horizon. Increasing Second Sight's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Second Sight Medical is useful when determining the fair value of the Second stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Second Sight. Since Second Sight is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Second Stock. However, Second Sight's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value.
Historical Market  4.14 Real  3.93 Hype  4.14 Naive  3.39
The real value of Second Stock, also known as its intrinsic value, is the underlying worth of Second Sight Medical Company, which is reflected in its stock price. It is based on Second Sight's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Second Sight's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Second Sight's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
3.93
Real Value
4.55
Upside
Estimating the potential upside or downside of Second Sight Medical helps investors to forecast how Second stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Second Sight more accurately as focusing exclusively on Second Sight's fundamentals will not take into account other important factors:
Bollinger
Band Projection (param)
LowerMiddle BandUpper
4.014.214.42
Details
Hype
Prediction
LowEstimatedHigh
4.144.144.14
Details
Naive
Forecast
LowNext ValueHigh
3.393.393.39
Details

Second Sight Valuation Ratios as Compared to Competition

Comparative valuation techniques use various fundamental indicators to help in determining Second Sight's current stock value. Our valuation model uses many indicators to compare Second Sight value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Second Sight competition to find correlations between indicators driving Second Sight's intrinsic value. More Info.
Second Sight Medical is one of the top stocks in price to book category among related companies. It is one of the top stocks in beta category among related companies totaling about  2.97  of Beta per Price To Book. . Comparative valuation analysis is a catch-all model that can be used if you cannot value Second Sight by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Second Sight's Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Second Sight's earnings, one of the primary drivers of an investment's value.
Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Second Sight's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Second Sight and how it compares across the competition.

About Second Sight Valuation

The delisted stock valuation mechanism determines the current worth of Second Sight Medical on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Second Sight Medical. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Second Sight Medical based exclusively on its fundamental and basic technical indicators. By analyzing Second Sight's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Second Sight's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Second Sight. We calculate exposure to Second Sight's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Second Sight's related companies.
Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. The company was founded in 1998 and is headquartered in Sylmar, California. Second Sight operates under Medical Devices classification in the United States and is traded on NAS Exchange. It employs 15 people.

8 Steps to conduct Second Sight's Valuation Analysis

Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Second Sight's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Second Sight's valuation analysis, follow these 8 steps:
  • Gather financial information: Obtain Second Sight's financial statements, including balance sheets, income statements, and cash flow statements.
  • Determine Second Sight's revenue streams: Identify Second Sight's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
  • Analyze market data: Research Second Sight's industry and market trends, including the size of the market, growth rate, and competition.
  • Establish Second Sight's growth potential: Evaluate Second Sight's management, business model, and growth potential.
  • Determine Second Sight's financial performance: Analyze its financial statements to assess its historical performance and future potential.
  • Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
  • Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Second Sight's estimated value.
  • Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Note: This is a general outline, and different approaches and methods may be used depending on the type and size of the company being valued. We also recomment to seek professional assistance to ensure accuracy.

Second Sight Growth Indicators

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Second Sight does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
Shares Percent Shares Out3.03%
Forward Price Earnings-2.96
Float Shares28.13M
Shares Short Prior Month1.37M
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.
Note that the Second Sight Medical information on this page should be used as a complementary analysis to other Second Sight's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .

Other Consideration for investing in Second Stock

If you are still planning to invest in Second Sight Medical check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Second Sight's history and understand the potential risks before investing.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
CEOs Directory
Screen CEOs from public companies around the world
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities